KetamineOne Capital Limited (NEO: MEDI) (“Ketamine One” or the “Company”) is focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working continuously to provide the critical infrastructure needed to develop and deliver breakthroughs in the field. Currently, Ketamine One has a network of 15 clinics through which it expects to deploy innovative technologies on an ongoing basis. The recent addition of KGK Science (“KGK”) as the Company’s contract research division also places Ketamine One at the medical forefront based on KGK’s 23-year history and growing experience with pharmaceuticals, cannabis, and psychedelics.
KGK Science -- Ketamine One’s wholly owned contract research organization
With demand for mental health treatments growing in the face of the coronavirus pandemic, the company sees huge potential to address the need for services with new psychedelic therapies combined with an emphasis on technology
A patient walking into a Ketamine One clinic in North America can expect to be offered a range of treatments, including psychedelic-assisted options, from a skilled medical professional and guided...